FDA Asks for Recalls of Sanofi's Zantac and All Generic Versions
The Food and Drug Administration has requested that Sanofi (NASDAQ: SNY) recall all of its Zantac heartburn products because the agency found that the amount of N-Nitrosodimethylamine (NDMA) in those products increases over time and when they are stored at higher than room temperatures. While consuming low levels of N-Nitrosodimethylamine has not been found to cause any health risks -- and the substance is found in foods and water -- sustained ingestion of higher levels is believed to increase the risk of developing cancer.
The request also extends to generic products that contain ranitidine, the active ingredient in Zantac, which are made by Novartis (NYSE: NVS), Endo (NASDAQ: ENDP), Dr. Reddy's Laboratories (NYSE: RDY), Perrigo (NYSE: PRGO), and others.
Image source: Getty Images.
Source Fool.com
